Philips wins court ruling over shareholder probe bid tied to device recall

Philips wins court ruling over shareholder probe bid tied to device recall
Philips wins recall dispute

Philips secures a Dutch court victory in a long-running dispute over its handling of the recall of sleep apnea devices that wiped out much of the health technology group's market value. The ruling rejects shareholder demands for an inquiry into whether the company misled investors or responded too slowly to emerging safety problems.

Highlights

  • Philips won a court ruling blocking a shareholder-led probe related to its major medical device recall.
  • Philips agreed in 2024 to pay $1.1 billion to settle all U.S. personal injury claims stemming from the device recall.
  • French prosecutors continue to investigate Philips over charges of aggravated fraud and failure to report safety risks linked to the recall.

Legal and financial fallout continues

According to Reuters, the court ruling narrows one avenue of pressure from investors, but the broader consequences of the recall continue across multiple jurisdictions. The case remains a significant episode for Philips as it manages litigation, regulatory scrutiny and reputational damage linked to the affected devices.

The recall has led to probes in several countries, including France, where prosecutors are still investigating charges of aggravated fraud and failure to report safety risks. In the U.S., Philips agreed in 2024 to pay $1.1 billion to settle all personal injury claims related to the devices.

Our earlier article examined how corporate dealmaking has been losing momentum despite record highs in the S&P 500, as rising yields and weaker confidence make investors more cautious. We noted that postponed IPOs and softer M&A volumes reflect tighter funding conditions, with higher borrowing costs and wider credit spreads making riskier capital raising less attractive even when headline equity benchmarks look resilient.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.